Lung Adenocarcinoma Clinical Trial
Official title:
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer
Verified date | February 2024 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, work in different ways to stop the growth of [cancer/tumor] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with radiation therapy and bevacizumab may kill more tumor cells.
Status | Active, not recruiting |
Enrollment | 29 |
Est. completion date | February 22, 2025 |
Est. primary completion date | July 1, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed single, primary, bronchogenic, non-small cell lung cancer (NSCLC) - Newly diagnosed disease - Unresectable disease - No more than 1 parenchymal lesions on same or opposite sides of the lungs - Meets 1 of the following stage criteria: - Stage IIIA (N2) disease meeting the following criteria: - N2 mediastinal lymph nodes must be multiple and/or bulky on CT scan or x-ray so that the patient is not a candidate for induction chemotherapy or chemoradiotherapy followed by surgical resection - N2 status must be documented by = 1 of the following methods: - Histologically or cytologically confirmed N2 disease by exploratory thoracotomy, thoracoscopy, mediastinoscopy, mediastinotomy, Chamberlain procedure, Wang needle biopsy (WNB), fine needle aspiration (FNA) under bronchoscopic or CT guidance, or any other method - Node positive by fludeoxyglucose-positron emission tomography (FDG-PET) scan - Nodes > 3 cm on CT scan - Paralyzed left true vocal cord with separate left lung primary distinct from anterior-posterior window nodes on CT scan - Stage IIIB disease meeting = 1 of the following criteria: - Histologically or radiographically confirmed positive N3 nodes*, documented by = 1 of the following methods: - FNA, core needle biopsy (CNB), or excisional biopsy of supraclavicular N3 nodes - Biopsy of contralateral mediastinal N3 nodes by mediastinoscopy, mediastinotomy, or thoracotomy - FNA, CNB, or WNB under CT or bronchoscopic fluoroscopic guidance of enlarged contralateral N3 mediastinal nodes - Contralateral mediastinal nodes > 3 cm on CT scan - Node positivity by FDG-PET scan - Right-sided primary with paralyzed left true vocal cord - T4 lesions of any size that invade the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina, documented by = 1 of the following methods: - Written documentation of type of T4 extent if patient had a prior exploratory thoracotomy or thoracoscopy - T4 involvement of the trachea or carina by direct bronchoscopic visualization - T4 involvement of the heart, esophagus, aorta, or vertebral body by CT scan, MRI, or transesophageal ultrasound - T4 involvement of the mediastinum by CT scan or MRI if, in the absence of the above organ involvement, there is soft tissue extension directly into the mediastinal space** - Meets 1 of the following risk criteria: - Low risk disease, meeting the following criteria: - Non-squamous cell NSCLC, including adenocarcinoma, bronchoalveolar cell carcinoma, or large cell carcinoma - If mixed histology, the squamous cell carcinoma component must be < 50% - Histology or cytology from involved mediastinal or supraclavicular lymph nodes allowed if a separate distal primary lesion is clearly evident on radiographs (i.e., second biopsy not required) - No primary tumor with cavitation and/or tumor within 1 cm of a major vessel - No hemoptysis (i.e., bright red blood = ½ teaspoon) in the past 28 days - High-risk* disease, meeting = 1 of the following criteria: - Squamous cell NSCLC - If mixed histology, the squamous cell component must be = 50% - Tumor with any histology that has cavitation or is located within 1 cm of a major vessel - No aortic involvement - Any histology and hemoptysis (i.e., bright red blood = ½ teaspoon) within past 28 days - Measurable or nonmeasurable disease by CT scan or MRI - Pleural effusions, ascites, and laboratory parameters are not acceptable as the only evidence of disease - No pleural effusion except for small pleural effusion visible on CT scan or MRI alone - No pericardial effusions - No metastatic disease involving the contralateral chest, liver, or adrenals confirmed by CT scan of the upper abdomen or by chest CT scan with complete liver and adrenals in the report - Patients must be offered participation in SWOG-S9925 (Lung Cancer Specimen Repository Protocol) - No brain metastases by CT scan or MRI - No evidence of cavitation - Creatinine normal - Creatinine clearance = 50 mL/min - FEV_1 = 2.0 liters OR predicted FEV_1 of the contralateral lung > 800 mL - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Urine protein: creatinine ratio = 0.5 by urinalysis OR urine protein < 1,000 mg by 24-hour urine collection - INR < 1.5 - Zubrod performance status 0-1 - No sensory neuropathy > grade 1 - No cerebrovascular accident within the past 6 months - No myocardial infarction or unstable angina within the past 6 months - No uncontrolled hypertension - No New York Heart Association class II-IV congestive heart failure - No serious cardiac arrhythmia requiring medication - No clinically significant peripheral vascular disease - No evidence of bleeding diathesis or coagulopathy - No pathologic condition other than lung cancer that carries a high risk of bleeding - No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies - No serious, nonhealing wound, ulcer, or bone fracture - No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or other cancer for which the patient has been disease-free for 5 years - Not pregnant or nursing - No nursing during and for = 6 months after the last dose of bevacizumab - Negative pregnancy test - Fertile patients must use effective contraception during and for = 6 months after the last dose of bevacizumab - Must have pre-treatment simulation demonstrating a V20 = 35% with planned radiation dose of 6,480 cGy - No prior surgical resection - Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery allowed for diagnosing, staging, or determining potential resectability of lung tumor - No prior chemotherapy or radiotherapy for lung cancer - No prior radiotherapy to the neck or thorax - At least 4 weeks since prior thoracic or other major surgery (excluding mediastinoscopy) and recovered - More than 7 days since prior FNA, CNB, or mediastinoscopy - No other concurrent anticancer therapy, including chemotherapy, radiotherapy, or biologic agents - No other concurrent investigational drugs - No concurrent major surgical procedures - No concurrent full-dose anticoagulants (e.g., low-molecular weight and unfractionated heparin or warfarin) - Low-dose warfarin (i.e., 1 mg) is allowed to prevent clotting of an infusaport or central line - No concurrent brachytherapy, radiopharmaceuticals, high linear energy transfer radiation (i.e., fast neutrons), particle therapy (i.e., protons, carbon, or helium), and/or altered fractionation schemes - No concurrent intensity-modulated radiotherapy - No concurrent prophylactic contralateral hilar or supraclavicular lymph node radiotherapy |
Country | Name | City | State |
---|---|---|---|
United States | The Don and Sybil Harrington Cancer Center | Amarillo | Texas |
United States | MultiCare Auburn Medical Center | Auburn | Washington |
United States | Rocky Mountain Regional VA Medical Center | Aurora | Colorado |
United States | UCHealth University of Colorado Hospital | Aurora | Colorado |
United States | Montana Cancer Consortium NCORP | Billings | Montana |
United States | Steward Saint Elizabeth's Medical Center | Brighton | Massachusetts |
United States | Providence Regional Cancer System-Centralia | Centralia | Washington |
United States | Roper Hospital | Charleston | South Carolina |
United States | Novant Health Presbyterian Medical Center | Charlotte | North Carolina |
United States | Danville Regional Medical Center | Danville | Virginia |
United States | Denver Health Medical Center | Denver | Colorado |
United States | University of Colorado | Denver | Colorado |
United States | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan |
United States | Shaw Cancer Center | Edwards | Colorado |
United States | Arnot Ogden Medical Center/Falck Cancer Center | Elmira | New York |
United States | Saint Francis Hospital | Federal Way | Washington |
United States | Valley View Hospital Cancer Center | Glenwood Springs | Colorado |
United States | Benefis Sletten Cancer Institute | Great Falls | Montana |
United States | HaysMed | Hays | Kansas |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | Hutchinson Regional Medical Center | Hutchinson | Kansas |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Saint Bernards Regional Medical Center | Jonesboro | Arkansas |
United States | Kansas City Veterans Affairs Medical Center | Kansas City | Missouri |
United States | University of Kansas Cancer Center | Kansas City | Kansas |
United States | Wellmont Holston Valley Hospital and Medical Center | Kingsport | Tennessee |
United States | Saint Clare Hospital | Lakewood | Washington |
United States | Cancer Centers of Central Florida PA | Leesburg | Florida |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Fremont - Rideout Cancer Center | Marysville | California |
United States | Loyola University Medical Center | Maywood | Illinois |
United States | University of Tennessee Health Science Center | Memphis | Tennessee |
United States | Providence Hospital | Mobile | Alabama |
United States | Montrose Memorial Hospital | Montrose | Colorado |
United States | McLaren Cancer Institute-Macomb | Mount Clemens | Michigan |
United States | Edward Hospital/Cancer Center | Naperville | Illinois |
United States | Southwest VA Regional Cancer Center | Norton | Virginia |
United States | Olathe Cancer Center | Olathe | Kansas |
United States | Providence - Saint Peter Hospital | Olympia | Washington |
United States | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Portland VA Medical Center | Portland | Oregon |
United States | MultiCare Good Samaritan Hospital | Puyallup | Washington |
United States | Highland Hospital | Rochester | New York |
United States | University of Rochester | Rochester | New York |
United States | Highlands Oncology Group - Rogers | Rogers | Arkansas |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Salina Regional Health Center | Salina | Kansas |
United States | Audie L Murphy VA Hospital | San Antonio | Texas |
United States | Cancer Therapy and Research Center at The UT Health Science Center at San Antonio | San Antonio | Texas |
United States | University Hospital | San Antonio | Texas |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
United States | Providence Santa Rosa Memorial Hospital | Santa Rosa | California |
United States | Lewis Cancer and Research Pavilion at Saint Joseph's/Candler | Savannah | Georgia |
United States | Highland Clinic | Shreveport | Louisiana |
United States | LSU Health Sciences Center at Shreveport | Shreveport | Louisiana |
United States | MultiCare Allenmore Hospital | Tacoma | Washington |
United States | Saint Joseph Medical Center | Tacoma | Washington |
United States | University of Kansas Health System Saint Francis Campus | Topeka | Kansas |
United States | Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee | California |
United States | Northbay Cancer Center | Vacaville | California |
United States | Southeast Clinical Oncology Research Consortium NCORP | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events | Only adverse events that are possibly, probably or definitely related to study drug are reported. | Up to one year | |
Secondary | Progression-free Survival | From date of registration to time of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. | Disease assessments were performed every 10 weeks as long as the patient remained on protocol treatment, up to 4 years. | |
Secondary | Overall Survival | From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. | Every week, up to 4 years | |
Secondary | Response Rate (Confirmed or Unconfirmed Partial Response) | Greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. | Response assessment occured at the end of CRT and docetaxel/bevacizumab and then every 2-3 months for 2 years and then every 6 months until 4 years after the initial registration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02898857 -
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
|
N/A | |
Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
Recruiting |
NCT01249066 -
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT04482829 -
TCM in the Treatment of Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Terminated |
NCT04691375 -
A Study of PY314 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT02621333 -
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02282267 -
Blood Detection of EGFR Mutation For Iressa Treatment
|
N/A | |
Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
Recruiting |
NCT01482585 -
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
|
N/A | |
Recruiting |
NCT03376737 -
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Recruiting |
NCT04937283 -
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
|
N/A | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Completed |
NCT02093000 -
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT04682431 -
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05736991 -
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
|
||
Enrolling by invitation |
NCT05136014 -
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
|
||
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 |